MABC1149
Anti-HAF/SART1 Antibody, clone 1-2
clone 1-2, from mouse
同義詞:
U4/U6.U5 tri-snRNP-associated protein 1, Allergen Hom s 1, HAF, hSART-1, hSnu66, SART-1, Hypoxia-associated factor, SNU66 homolog, Squamous cell carcinoma antigen recognized by T-cells 1, U4/U6.U5 tri-snRNP-associated 110 kDa protein
登入查看組織和合約定價
全部照片(7)
About This Item
生物源
mouse
品質等級
抗體表格
purified antibody
抗體產品種類
primary antibodies
無性繁殖
1-2, monoclonal
物種活性
human
技術
immunocytochemistry: suitable
immunohistochemistry: suitable
western blot: suitable
同型
IgG1κ
NCBI登錄號
UniProt登錄號
運輸包裝
ambient
目標翻譯後修改
unmodified
基因資訊
human ... SART1(9092)
一般說明
U4/U6.U5 tri-snRNP-associated protein 1 (UniProt O43290; also known as Allergen Hom s 1, HAF, hSART-1, hSnu66, Hypoxia-associated factor, SART-1, SNU66 homolog, Squamous cell carcinoma antigen recognized by T-cells 1, U4/U6.U5 tri-snRNP-associated 110 kDa protein) is encoded by the SART1 (also known as HAF) gene (Gene ID 9092) in human. The hypoxia-associated factor (HAF) is an E3 ubiquitin ligase that mediates the ubiquitination and degradation of hypoxia-inducible factor 1α (HIF-1α). HAF also binds to HIF-2α and promotes HIF-2 transactivation instead of promoting HIF-2α degradation. In addition, hypoxia-dependent HAF SUMOylation enhances HAF interaction with HIF-2α and induction of HIF-2 target genes transcription, such as OCT-3/4, SOX2 and NANOG. HAF therefore promotes stem cell characteristics, aggressive tumor growth and invasion by switching cells from HIF-1α- to HIF-2α-dependent signaling. HAF overexpression enhances glioblastoma cells that express both HIF-1α and HIF-2α to initiate tumors as intracranial xenografts in mice. On the other hand, HAF overexpression results in decreased xenograft tumor growth of HT29 colon carcinoma cells that only express HIF-1α.
特異性
Clone 1-2 detected HAF shRNA-mediated HAF knockdown in MIA PaCa-2 human pancreatic carcinoma cells.
免疫原
GST-tagged recombinant human HAF/SART1 C-terminal fragment.
應用
Detect HAF/SART1 using this mouse monoclonal Anti-HAF/SART1, clone 1-2 Antibody, Cat. No. MABC1149, validated for use in Western Blotting and Immunocytochemistry, Immunohistochemistry, and Western Blotting.
Immunocytochemistry Analysis: A 1:200 dilution from a representative lot detected HAF/SART1 in A431 cells.
Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of Jurkat cell lysate.
Immunocytochemistry Analysis: A representative lot detected a reduced HAF immunoreactivity in MIA PaCa-2 human pancreatic carcinoma cells following HAF shRNA treatment (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunocytochemistry Analysis: A representative lot detected HAF in HeLa and PANC-1 cells (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunocytochemistry Analysis: A representative lot detected an increased HAF immunoreactivity in 786-O human kidney cancer cells transfected to overexpress HAF (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunohistochemistry Analysis: A representative lot detected HAF immunoreactivity in 786-O xenograft (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of Jurkat cell lysate.
Immunocytochemistry Analysis: A representative lot detected a reduced HAF immunoreactivity in MIA PaCa-2 human pancreatic carcinoma cells following HAF shRNA treatment (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunocytochemistry Analysis: A representative lot detected HAF in HeLa and PANC-1 cells (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunocytochemistry Analysis: A representative lot detected an increased HAF immunoreactivity in 786-O human kidney cancer cells transfected to overexpress HAF (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Immunohistochemistry Analysis: A representative lot detected HAF immunoreactivity in 786-O xenograft (Courtesy of Mei Yee Koh, Ph.D., Sanford-Burnham Medical Research Institute, La Jolla, CA USA).
Research Category
Apoptosis & Cancer
Apoptosis & Cancer
品質
Evaluated by Western Blotting in HeLa cell lysate.
Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of HeLa cell lysate.
Western Blotting Analysis: A 1:62.5 dilution from a representative lot detected HAF/SART1 in 10 µg of HeLa cell lysate.
標靶描述
~110 kDa observed. 90.26 kDa calculated. The larger-than-calculated target band size is consistent with that reported in the literature (Koh, M.Y. et al. (2015). Cancer Res. 75(2):316-329). Uncharacterized bands may be observed in some lysate(s).
外觀
Protein G purified.
Format: Purified
Purified mouse IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide
儲存和穩定性
Stable for 1 year at 2-8°C from date of receipt.
其他說明
Concentration: Please refer to lot specific datasheet.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到適合的產品?
試用我們的產品選擇工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務